Literature DB >> 7532678

Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

D J Lenschow1, S C Ho, H Sattar, L Rhee, G Gray, N Nabavi, K C Herold, J A Bluestone.   

Abstract

Insulin-dependent diabetes mellitus (IDDM) is thought to be an immunologically mediated disease resulting in the complete destruction of the insulin-producing islets of Langerhans. It has become increasingly clear that autoreactive T cells play a major role in the development and progression of this disease. In this study, we examined the role of the CD28/B7 costimulation pathway in the development and progression of autoimmune diabetes in the nonobese diabetic (NOD) mouse model. Female NOD mice treated at the onset of insulitis (2-4 wk of age) with CTLA4Ig immunoglobulin (Ig) (a soluble CD28 antagonist) or a monoclonal antibody (mAb) specific for B7-2 (a CD28 ligand) did not develop diabetes. However, neither of these treatments altered the disease process when administered late, at > 10 wk of age. Histological examination of islets from the various treatment groups showed that while CTLA4Ig and anti-B7-2 mAb treatment blocked the development of diabetes, these reagents had little effect on the development or severity of insulitis. Together these results suggest that blockade of costimulatory signals by CTLA4Ig or anti-B7-2 acts early in disease development, after insulitis but before the onset of frank diabetes. NOD mice were also treated with mAbs to another CD28 ligand, B7-1. In contrast to the previous results, the anti-B7-1 treatment significantly accelerated the development of disease in female mice and, most interestingly, induced diabetes in normally resistant male mice. A combination of anti-B7-1 and anti-B7-2 mAbs also resulted in an accelerated onset of diabetes, similar to that observed with anti-B7-1 mAb treatment alone, suggesting that anti-B7-1 mAb's effect was dominant. Furthermore, treatment with anti-B7-1 mAbs resulted in a more rapid and severe infiltrate. Finally, T cells isolated from the pancreas of these anti-B7-1-treated animals exhibited a more activated phenotype than T cells isolated from any of the other treatment groups. These studies demonstrate that costimulatory signals play an important role in the autoimmune process, and that different members of the B7 family have distinct regulatory functions during the development of autoimmune diabetes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532678      PMCID: PMC2191918          DOI: 10.1084/jem.181.3.1145

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  57 in total

1.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones.

Authors:  F A Harding; J G McArthur; J A Gross; D H Raulet; J P Allison
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

2.  B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.

Authors:  C D Gimmi; G J Freeman; J G Gribben; K Sugita; A S Freedman; C Morimoto; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

3.  Characterization of pancreatic islet cell infiltrates in NOD mice: effect of cell transfer and transgene expression.

Authors:  L A O'Reilly; P R Hutchings; P R Crocker; E Simpson; T Lund; D Kioussis; F Takei; J Baird; A Cooke
Journal:  Eur J Immunol       Date:  1991-05       Impact factor: 5.532

4.  Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone.

Authors:  K Haskins; M McDuffie
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

5.  CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression.

Authors:  A Risso; D Smilovich; M C Capra; I Baldissarro; G Yan; A Bargellesi; M E Cosulich
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

6.  Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway.

Authors:  A S Freedman; G J Freeman; K Rhynhart; L M Nadler
Journal:  Cell Immunol       Date:  1991-10-15       Impact factor: 4.868

7.  T-lymphocyte-receptor repertoire of infiltrating T lymphocytes into NOD mouse pancreas.

Authors:  T Maeda; T Sumida; K Kurasawa; H Tomioka; I Itoh; S Yoshida; T Koike
Journal:  Diabetes       Date:  1991-12       Impact factor: 9.461

8.  Identification and distribution of the costimulatory receptor CD28 in the mouse.

Authors:  J A Gross; E Callas; J P Allison
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

9.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.

Authors:  P S Linsley; W Brady; L Grosmaire; A Aruffo; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

10.  CTLA-4 is a second receptor for the B cell activation antigen B7.

Authors:  P S Linsley; W Brady; M Urnes; L S Grosmaire; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

View more
  140 in total

Review 1.  The molecular basis of T cell differentiation.

Authors:  R A Flavell
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

Review 3.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 4.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

5.  CD28-independent induction of experimental autoimmune encephalomyelitis.

Authors:  T Chitnis; N Najafian; K A Abdallah; V Dong; H Yagita; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

6.  CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.

Authors:  K L Neville; M C Dal Canto; J A Bluestone; S D Miller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 7.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 8.  Immunomodulation by interference with co-stimulatory molecules: therapeutic perspectives in asthma.

Authors:  S E Burastero; G A Rossi
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

9.  Marked suppression of T cells by a benzothiophene derivative in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  M Makino; M Azuma; S I Wakamatsu; Y Suruga; S Izumo; M M Yokoyama; M Baba
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

10.  CD86 (B7-2), but not CD80 (B7-1), expression in the epidermis of transgenic mice enhances the immunogenicity of primary cutaneous Candida albicans infections.

Authors:  A A Gaspari; R Burns; A Nasir; D Ramirez; R K Barth; C G Haidaris
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.